United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction on Friday, November 13th. The shares were sold at an average price of $592.42, for a total transaction of $5,627,990.00. Following the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at $192,206,522.06. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
United Therapeutics Stock Down 0.6%
UTHR stock opened at $587.88 on Tuesday. The business's fifty day moving average is $544.61 and its 200-day moving average is $536.98. The company has a market cap of $25.04 billion, a P/E ratio of 22.18, a price-to-earnings-growth ratio of 3.94 and a beta of 0.49. United Therapeutics Corporation has a twelve month low of $455.63 and a twelve month high of $614.23.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The company had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. During the same quarter in the prior year, the business earned $7.16 earnings per share. The firm's revenue for the quarter was up 4.1% on a year-over-year basis. Research analysts anticipate that United Therapeutics Corporation will post 25.08 earnings per share for the current fiscal year.
United Therapeutics announced that its Board of Directors has initiated a stock repurchase program on Thursday, October 22nd that allows the company to repurchase $2 billion in shares. This repurchase authorization allows the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its shares are undervalued.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $710.00 to $695.00 and set an "overweight" rating on the stock in a report on Wednesday, October 28th. BTIG Research boosted their price objective on shares of United Therapeutics from $728.00 to $768.00 and gave the company a "buy" rating in a research report on Wednesday, November 4th. Weiss Ratings lowered shares of United Therapeutics from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, November 9th. HC Wainwright began coverage on United Therapeutics in a report on Monday, November 9th. They set a "buy" rating and a $660.00 target price for the company. Finally, UBS Group set a $725.00 target price on United Therapeutics in a report on Monday, October 19th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $676.40.
Check Out Our Latest Research Report on UTHR
Hedge Funds Weigh In On United Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. Arjuna Capital raised its position in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after acquiring an additional 18 shares in the last quarter. Meeder Advisory Services Inc. grew its position in shares of United Therapeutics by 3.0% in the 3rd quarter. Meeder Advisory Services Inc. now owns 657 shares of the biotechnology company's stock valued at $356,000 after acquiring an additional 19 shares during the period. Abacus Wealth Partners LLC grew its position in shares of United Therapeutics by 5.6% in the 3rd quarter. Abacus Wealth Partners LLC now owns 396 shares of the biotechnology company's stock valued at $215,000 after acquiring an additional 21 shares during the period. Parallel Advisors LLC grew its position in shares of United Therapeutics by 2.1% in the 3rd quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company's stock valued at $625,000 after acquiring an additional 24 shares during the period. Finally, Benjamin Edwards Inc. increased its stake in shares of United Therapeutics by 5.1% during the 3rd quarter. Benjamin Edwards Inc. now owns 497 shares of the biotechnology company's stock worth $269,000 after purchasing an additional 24 shares during the last quarter. 94.08% of the stock is owned by institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].